Among recipients of the combinatory ICI regimens, cancer patients exposed to a combination of anti-PD-1 and anti-CTLA-4 exhibited elevated hazard ratios associated with uveitis development (HR: 5.04 [CI:3.55-7.16]) compared to their non-ICI comparators. The gene discussed is CTLA4; the disease is cancer.